Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / COVID-19 - Page 11

COVID-19

Gilead Sciences signed joint procurement agreement with the European Commission for Vekluryᆴ (Remdesivir)
COVID-19 | Life Science History

Gilead Sciences signed joint procurement agreement with the European Commission for Vekluryᆴ (Remdesivir)

On Jul. 19, 2022, Gilead Sciences and the European Commission announced a new joint procurement agreement (JPA) that…

Read More Gilead Sciences signed joint procurement agreement with the European Commission for Vekluryᆴ (Remdesivir)Continue

Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
Biotechnology | COVID-19 | Therapeutics | Vaccine

Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years

On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…

Read More Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five yearsContinue

Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)

On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…

Read More Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)Continue

U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for individuals aged 18 and over
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for individuals aged 18 and over

On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from…

Read More U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for individuals aged 18 and overContinue

Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17

On Jul. 13, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…

Read More Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17Continue

NIH launched clinical trial of mRNA Nipah virus vaccine
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine

NIH launched clinical trial of mRNA Nipah virus vaccine

On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…

Read More NIH launched clinical trial of mRNA Nipah virus vaccineContinue

Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response

On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…

Read More Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody responseContinue

U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccine
COVID-19 | NIH | Therapeutics | Vaccine

U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccine

On Jul. 11, 2022, Novavax announced an agreement with the U.S. Department of Health and Human Services (HHS),…

Read More U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccineContinue

Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY
Biotechnology | COVID-19 | Life Science History | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY

On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…

Read More Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATYContinue

European Medicines Agency approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

European Medicines Agency approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccine

On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…

Read More European Medicines Agency approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccineContinue

Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17

On Jul. 5, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…

Read More Novavax Nuvaxovid COVID-19 vaccine conditionally authorized in EU for adolescents aged 12 through 17Continue

COVID-19 was third leading cause of death in the United States in both 2020 and 2021
COVID-19 | NIH

COVID-19 was third leading cause of death in the United States in both 2020 and 2021

On Jul. 5, 2022, the National Institutes of Health and National Cancer Institute announced COVID-19 was the third…

Read More COVID-19 was third leading cause of death in the United States in both 2020 and 2021Continue

NIH study revealed how immune response triggered by COVID-19 may damage the brain
COVID-19 | Life Science History

NIH study revealed how immune response triggered by COVID-19 may damage the brain

On Jul. 5, 2022, the National Institutes of Health released a study that described the immune response triggered…

Read More NIH study revealed how immune response triggered by COVID-19 may damage the brainContinue

Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID
Biotechnology | COVID-19 | FDA | Infectious Disease | Therapeutics

Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVID

On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…

Read More Pfizer announced submission of New Drug Application to the U.S. FDA for PAXLOVIDContinue

Pfizer and BioNTech announced agreement with U.S. Government to provide additional doses of COVID-19 Vaccine
COVID-19 | FDA | Life Science History

Pfizer and BioNTech announced agreement with U.S. Government to provide additional doses of COVID-19 Vaccine

On Jun. 30, 2022, Pfizer and BioNTech announced a vaccine supply agreement with the U.S. government to support…

Read More Pfizer and BioNTech announced agreement with U.S. Government to provide additional doses of COVID-19 VaccineContinue

BD launched combination test for COVID-19, Influenza A/B and Respiratory Syncytial Virus
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Medical Device

BD launched combination test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…

Read More BD launched combination test for COVID-19, Influenza A/B and Respiratory Syncytial VirusContinue

COVID-19 Wheel of Fortune
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Disease | FDA | Life Science History | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 Wheel of Fortune

Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…

Read More COVID-19 Wheel of FortuneContinue

Pfizer and BioNTech announced Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response
COVID-19 | Life Science History | Vaccine

Pfizer and BioNTech announced Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response

On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…

Read More Pfizer and BioNTech announced Omicron-adapted COVID-19 vaccine candidates demonstrated high immune responseContinue

Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents

On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…

Read More Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescentsContinue

Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17

On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…

Read More Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17Continue

Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over

On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…

Read More Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and overContinue

Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants

On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…

Read More Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variantsContinue

Pfizer-BioNTech COVID-19 vaccine received FDA Emergency Use Authorization for children 6 months through 4 years of age
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Pfizer-BioNTech COVID-19 vaccine received FDA Emergency Use Authorization for children 6 months through 4 years of age

On Jun. 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration (FDA) had granted emergency…

Read More Pfizer-BioNTech COVID-19 vaccine received FDA Emergency Use Authorization for children 6 months through 4 years of ageContinue

Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older

On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…

Read More Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and olderContinue

Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine
COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine

On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…

Read More Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccineContinue

Roche received FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and measure viral load levels of COVID-19
COVID-19 | Life Science History

Roche received FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and measure viral load levels of COVID-19

On Jun. 15, 2022, Roche announced that the US Food and Drug Administration had issued Emergency Use Authorization…

Read More Roche received FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and measure viral load levels of COVID-19Continue

Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA

On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…

Read More Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDAContinue

Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over

On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…

Read More Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and overContinue

Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron

On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…

Read More Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against OmicronContinue

Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study
Biotechnology | COVID-19 | Therapeutics

Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study

On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…

Read More Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT studyContinue

Page navigation

Previous PagePrevious 1 … 9 10 11 12 13 … 99 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiovascular
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search